Is Innova Captab overvalued or undervalued?

As of 30 October 2025, the valuation grade for Innova Captab has moved from attractive to fair. The company is currently fairly valued based on its financial metrics. Key ratios include a PE Ratio of 36.65, an EV to EBITDA of 25.64, and a ROE of 13.37%.
In comparison to its peers, Innova Captab's PE Ratio is slightly higher than Sun Pharma's 35.63, which is considered expensive, while it is significantly lower than Divi's Lab's very expensive PE of 76.52. Additionally, the PEG Ratio of 1.02 indicates that the stock is reasonably priced relative to its growth expectations. Notably, over the past year, Innova Captab has outperformed the Sensex with a return of 9.38% compared to the Sensex's 5.58%.